Anna Lundin

Anna Lundin is a research scientist at Mabtech AB since November 2015, actively contributing to the Hybridoma group in the development of new monoclonal antibodies for ELISA, ELISpot, and Fluorospot applications. Prior to this role, Anna served as a laboratory engineer at AstraZeneca and Karolinska Universitetssjukhuset, focusing on quality assurance and clinical microbiology, respectively. Anna also has experience as a teaching assistant at Uppsala University and worked as an adventure guide from 2001 to 2007. Anna holds a Master of Science in Biology from Uppsala University and studied at The Australian National University.